Balance of care activity after EMA recommendation for DPYD gene testing in Galicia

Balance of care activity after EMA recommendation for DPYD gene testing in Galicia

IntroductionSince April 2020, pretherapeutic screening for accessing the deficiency of the DPD enzyme by genotyping the dihydropyrimidine dehydrogenase gene (DPYD) is required by the European Medicine Agency (EMA) prior to the administration of fluoropyrimidine-based chemotherapy. In May 2020, the S...

Full description

Saved in:
Bibliographic Details
Main Authors: Almudena Gil-Rodríguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Francisco Barros, Angel Carracedo, Olalla Maroñas
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
fluoropyrimidines
DPYD
implementation
pharmacogenetics
adverse-drugreaction
EMA
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1523536/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1523536/full

Similar Items